Preparation and characterization of novel albumin-sericin nanoparticles as siRNA delivery vehicle for laryngeal cancer treatment

Yalçın, Elif; Kara, Göknur; Çelik, Ekin; Pınarlı, Ferda Alpaslan; Saylam, Güleser; Sucularli, Ceren; Öztürk, Serpil; Yılmaz, Ebru Şebnem; Bayır, Ömer; Korkmaz, Mehmet; Denkbaş, Emir Baki

doi:10.1080/10826068.2019.1599395

Cited by 38 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biggest hurdle has been delivery as siRNAs do not readily cross the cell membrane. Various approaches have been proposed to solve the problem of siRNA delivery in vivo, for example, viruses, cationic lipids, polymers, and nanoparticles [10,11]. One of the most promising approaches to improve the delivery and safety of siRNA is bioconjugation, the covalent connection of siRNAs with biogenic molecules, such as lipophilic molecules, antibodies, aptamers, ligands, peptides, or polymers, which also cause less immunoreaction [12,13].…”

Section: Key Pointsmentioning

confidence: 99%

Targeting angiotensinogen with RNA-based therapeutics

Ren

Colafella

Bovée

et al. 2020

Current Opinion in Nephrology and Hypertension

View full text Add to dashboard Cite

Purpose of review To summarize all available data on targeting angiotensinogen with RNA-based therapeutics as a new tool to combat cardiovascular diseases. Recent findings Liver-targeted, stable antisense oligonucleotides and small interfering RNA targeting angiotensinogen are now available, and may allow treatment with at most a few injections per year, thereby improving adherence. Promising results have been obtained in hypertensive animal models, as well as in rodent models of atherosclerosis, polycystic kidney disease and pulmonary fibrosis. The next step will be to evaluate the optimal degree of suppression, synergy with existing renin-angiotensin-aldosterone system blockers, and to determine harmful effects of suppressing angiotensinogen in the context of common comorbidities, such as heart failure and chronic kidney disease.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Targeting angiotensinogen with RNA-based therapeutics

Ren

Colafella

Bovée

et al. 2020

Current Opinion in Nephrology and Hypertension

View full text Add to dashboard Cite

show abstract

“…As a result of multiple connective tissue barriers in the larynx, a number of studies have focused on the targeting or sustained release system to reduce frequency of multiple dosing and adverse effects. The existing laryngeal deposition strategies mainly include lipids 5 , 6 , nanoparticles 7 , 8 , throat sprays 9 , and lozenges 10 . Lipids and nanoparticles provide a slow-release delivery system for bioactive agents in the larynx, but they are usually limited by rapid clearance and metabolism from the injection site 5 , 11 .…”

Section: Introductionmentioning

confidence: 99%

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Zhao

Guo

Wang

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

It is essential to develop new carriers for laryngeal drug delivery in light of the lack of therapy in laryngeal related diseases. When the inhalable micron-sized crystals of γ -cyclodextrin metal-organic framework (CD-MOF) was utilized as dry powder inhalers (DPIs) carrier with high fine particle fraction (FPF), it was found in this research that the encapsulation of a glycoside compound, namely, scutellarin (SCU) in CD-MOF could significantly enhance its laryngeal deposition. Firstly, SCU loading into CD-MOF was optimized by incubation. Then, a series of characterizations were carried out to elucidate the mechanisms of drug loading. Finally, the laryngeal deposition rate of CD-MOF was 57.72 ± 2.19% improved by SCU, about two times higher than that of CD-MOF, when it was determined by Next Generation Impactor (NGI) at 65 L/min. As a proof of concept, pharyngolaryngitis therapeutic agent dexamethasone (DEX) had improved laryngeal deposition after being co-encapsulated with SCU in CD-MOF. The molecular simulation demonstrated the configuration of SCU in CD-MOF and its contribution to the free energy of the SCU@CD-MOF, which defined the enhanced laryngeal anchoring. In conclusion, the glycosides-like SCU could effectively enhance the anchoring of CD-MOF particles to the larynx to facilitate the treatment of laryngeal diseases.

show abstract

“…NPs were loaded with siRNA targeting casein kinase 2 (CK2), Absent, Small, or Homeotic-Like (ASH2L), and Cyclin D1 (CCND1) genes, which are overexpressed in Hep-2 cells. The silencing effect achieved by individual administration of Alb-Ser NPs targeting the mentioned above genes was significantly higher (45-65%) compared with naked siRNA and resulted in significant cytotoxicity of targeted cells [130].…”

Section: Cancer Treatment Using Silk-based Nanoparticles Loaded With Nucleic Acid-based Therapeuticsmentioning

confidence: 95%

“…Not only silk fibroin but also the other main B. mori silkworm cocoon component-sericin was successfully used in the formulation of nanoparticles for nucleic acid delivery. Yalcin et al investigated the delivery of siRNA into Hep-2 laryngeal cancer cells using albumin-sericin nanoparticles (Alb-Ser NPs) [130]. The Alb-Ser NPs had a mean size of 117 nm and were synthesized by the desolvation method.…”

Section: Cancer Treatment Using Silk-based Nanoparticles Loaded With Nucleic Acid-based Therapeuticsmentioning

confidence: 99%

Silk Particles as Carriers of Therapeutic Molecules for Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

Although progress is observed in cancer treatment, this disease continues to be the second leading cause of death worldwide. The current understanding of cancer indicates that treating cancer should not be limited to killing cancer cells alone, but that the target is the complex tumor microenvironment (TME). The application of nanoparticle-based drug delivery systems (DDS) can not only target cancer cells and TME, but also simultaneously resolve the severe side effects of various cancer treatment approaches, leading to more effective, precise, and less invasive therapy. Nanoparticles based on proteins derived from silkworms’ cocoons (like silk fibroin and sericins) and silk proteins from spiders (spidroins) are intensively explored not only in the oncology field. This natural-derived material offer biocompatibility, biodegradability, and simplicity of preparation methods. The protein-based material can be tailored for size, stability, drug loading/release kinetics, and functionalized with targeting ligands. This review summarizes the current status of drug delivery systems’ development based on proteins derived from silk fibroin, sericins, and spidroins, which application is focused on systemic cancer treatment. The nanoparticles that deliver chemotherapeutics, nucleic acid-based therapeutics, natural-derived agents, therapeutic proteins or peptides, inorganic compounds, as well as photosensitive molecules, are introduced.

show abstract

Preparation and characterization of novel albumin-sericin nanoparticles as siRNA delivery vehicle for laryngeal cancer treatment

Cited by 38 publications

References 38 publications

Targeting angiotensinogen with RNA-based therapeutics

Targeting angiotensinogen with RNA-based therapeutics

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Silk Particles as Carriers of Therapeutic Molecules for Cancer Treatment

Contact Info

Product

Resources

About